Special Engineer

We are looking for a highly motivated Special Engineer to join our team at the Translational Research Unit, Section of Cellular therapy, Oslo University Hospital-Radium Hospital, Norway. The section is home to one of Europe’s biggest and most modern GMP facilities for cellular products.

The Section for Cellular Therapy is home to one of Europe’s biggest and most modern GMP facilities for cellular products and also provides cellular products for industry trials abroad. The section counts 35 employees split in a clinical ward and the Translational Research Unit (18 employees), which is developing pre-clinical solutions in cancer immunotherapy. These include TCR, CAR and vaccine research. We have produced the first Norwegian CAR molecule, anti-CD37CAR (Köksal, Dillard et al. 2019, Caulier et al. 2024 in press), among a collection of almost 20 prepared either from our own stock of antibodies or from antibodies we generated ourselves (Köksal, Baken, et al. 2019). Our facility has the capacity to run pre-clinical validations of CAR molecules. We also develop therapeutic TCR, and Radium-1 TCR was also the first ever tested in an academic clinical trial in Scandinavia (Maggadottir et al. 2024). Our discoveries have led to the establishment of two biotechs: Ultimovacs and Zelluna Immunotherapy AS. Our unit is located at the Oslo Cancer Cluster Incubator (https://occincubator.com/), next to the Radium Hospital.

Oslo University Hospital is a workplace with great diversity. We believe this is essential to perform the tasks required of us. Therefore, we pursue diversity among our job applicants and encourage everyone to apply regardless of who you are and what background you have.
 

Job/ Project description

The successful candidate will integrate an international and collaborative scientific team working on delivering
immunotherapeutic solutions for hard-to-beat cancers, where she/he will
contribute by driving pre-clinical projects forward. The present project is
part of a larger national effort to enhance cellular therapy products. More
specifically, the main tasks of the candidate will be optimising culture
conditions and genetic engineering (transduction, transfection) in order to
discover novel formulations for enhanced therapeutic T cells and testing their
efficacy against tumour cell lines and primary patient material. Furthermore, the candidate main task will be to run in vivo testing of therapeutic T cells in murine xenograft models. The candidate will as all lab members have responsibilities for lab duties such as cleaning and maintenance of the
instruments/devices and daily running of the lab. Finally, the candidate will
participate in an active program of scientific discussions through regular team
meetings and collaborations with other research groups.

This is a limited term appointment with funding for this post available for a period
of 1 year from 1st June 2024 in the first instance, with the possibility of
extension. Some flexibility with respect to work hours will be required
occasionally.

Qualifications

Applicants must have a university degree (min. Master degree in science or equivalent in pharmacy, veterinary science or medicine) and possess a valid
certification for animal experimentation (CareIn, FELASA C). We are seeking
candidates that are trained in monitoring of tumour growth (through IVIS or
PET-SCAN) and different types of injection (ip, iv, sc).  

Experience in surgery will be considered.

Experience in immunology and cell biology, specifically with T cell culture and related
assays (cytotoxic assays, cytokine detection, etc.) and the ability to manipulate
a flow cytometer independently (analysis and/or sorting) will be an advantage.

Knowledge in molecular biology will also be considered as a plus.

Although English is the main language used in the lab, command in one of the
Scandinavian languages will also be considered an advantage. 

The application must include the following

• Application letter (1 page max) depicting previous in vivo experience
• CV (2 pages max, summarizing education, positions, and other qualifying activities)
• Copies and transcripts of educational certificates and diplomas

Names and contact details of 2) references (name, relation to candidate, e-mail and telephone number)  Please respect the document length: exceeding document size and addition of unrequested documents might lead to disqualification

Informal enquiries can be addressed to Dr Else Marit Inderberg: elsin@rr-research.no

For more information on the work of the group, please visit here: http://celltherapy.no/

Kontaktinformasjon

Else Marit Inderberg, Unit leader, +4746448620, elsin@rr-research.no

Arbeidssted

Ullernchausseen 64
0379 Oslo

Nøkkelinformasjon:

Arbeidsgiver: Oslo universitetssykehus HF

Referansenr.: 4802636376
Stillingsprosent: 100%
Contract
Sluttdato: 31.05.2025
Søknadsfrist: 10.05.2024

DIVERSE INFO

Kilde: NAV stillingsannonser
https://arbeidsplassen.nav.no/stillinger/stilling/9ffb4e15-7a6a-4c5a-b021-b88ed2c6937f
IMPORTAPI